Clinical Trials Logo

Pain, Inflammatory clinical trials

View clinical trials related to Pain, Inflammatory.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03485365 Completed - Pain, Inflammatory Clinical Trials

A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)

Start date: May 17, 2018
Phase: Phase 1
Study type: Interventional

This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of either a single intravenous (IV) or a single subcutaneous (SC) dose. Approximately 48 healthy participants will be enrolled in 6 cohorts and randomized to 3:1 ratio (GSK3858279 or placebo). Part B will evaluate safety, tolerability, efficacy (pain), PK, TE and immunogenicity after repeat SC dosing. Approximately 50 OA participants will be randomized in a parallel group design to receive either GSK3858279 or placebo in a 1:1 ratio.

NCT ID: NCT00849134 Completed - Pain, Inflammatory Clinical Trials

First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.

Start date: November 17, 2008
Phase: Phase 1
Study type: Interventional

This is a first-time-in-human study. The overall purpose of the study is to assess whether the drug is safe and well tolerated after single, increasing doses. At different doses, we will look to see how much of the drug gets into the bloodstream, how the drug is broken down and excreted and whether this is affected by the presence of food.

NCT ID: NCT00511524 Completed - Pain, Inflammatory Clinical Trials

An Imaging Study to Investigate the Distribution of GW842166X in the Brain.

Start date: June 26, 2007
Phase: Phase 1
Study type: Interventional

GW842166X is being developed for the treatment and management of inflammatory pain. GW842166X is a CB2 receptor agonist and the mechanism is not fully understood, although it is thought that for the anti-inflammatory action the drug is required to cross inot the brain from the blood. This study aims to look at if the drug crosses into the brain once given orally using an imaging technique called positron emission tomography.